Evolus (NASDAQ:EOLS) PT Raised to $20.00

Evolus (NASDAQ:EOLS – Get Rating) had its price target lifted by SVB Leerink from $18.00 to $20.00 in a research note issued on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the stock. SVB Leerink’s price target indicates a potential upside of 81.00% from the company’s previous close.

Other equities research analysts have also recently issued research reports about the stock. Mizuho upped their price objective on shares of Evolus from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Thursday. HC Wainwright reaffirmed a “buy” rating on shares of Evolus in a research note on Wednesday, November 9th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $16.67.

Evolus Price Performance

EOLS stock opened at $11.05 on Thursday. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.26 and a quick ratio of 1.84. Evolus has a one year low of $5.06 and a one year high of $14.34. The stock has a market cap of $621.53 million, a PE ratio of -7.78 and a beta of 1.83. The firm has a 50 day simple moving average of $7.70 and a two-hundred day simple moving average of $9.09.

Evolus (NASDAQ:EOLS – Get Rating) last released its quarterly earnings results on Tuesday, November 8th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.05). Evolus had a negative return on equity of 141.07% and a negative net margin of 56.88%. The company had revenue of $33.90 million during the quarter, compared to analysts’ expectations of $36.94 million. On average, analysts predict that Evolus will post -1.12 EPS for the current fiscal year.

Institutional Investors Weigh In On Evolus

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Point72 Hong Kong Ltd raised its holdings in Evolus by 979.7% during the 1st quarter. Point72 Hong Kong Ltd now owns 2,343 shares of the company’s stock valued at $26,000 after buying an additional 2,126 shares during the last quarter. Metropolitan Life Insurance Co NY bought a new stake in Evolus during the 1st quarter valued at $26,000. Tower Research Capital LLC TRC raised its holdings in Evolus by 453.6% in the 3rd quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock worth $51,000 after purchasing an additional 5,221 shares in the last quarter. Ensign Peak Advisors Inc bought a new position in Evolus in the 3rd quarter worth $54,000. Finally, Amalgamated Bank bought a new position in Evolus in the 1st quarter worth $61,000. 45.41% of the stock is currently owned by institutional investors.

Evolus Company Profile

(Get Rating)

Evolus, Inc is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.